LOSE WEIGHT WITH MEDICAL SUPPORT — BUILT FOR MEN
- Your personalised programme is built around medical care, not willpower.
- No generic diets. No guesswork.
- Just science-backed results and expert support.
Find out if you’re eligible
Starting Wegovy (semaglutide 2.4 mg) for weight management involves a carefully structured treatment journey with gradual dose escalation, lifestyle modifications, and regular monitoring. As a GLP-1 receptor agonist licensed in the UK for adults with obesity or overweight with comorbidities, Wegovy reduces appetite and supports sustainable weight loss when combined with dietary changes and increased physical activity. Understanding what to expect—from initial side effects to realistic weight loss timelines—helps you prepare for treatment and maximise results. This guide provides evidence-based information on Wegovy administration, common experiences, and how to work effectively with your healthcare team throughout your weight management programme.
Quick Answer: Wegovy is a once-weekly GLP-1 receptor agonist injection that reduces appetite and supports weight loss through gradual dose escalation over 16–20 weeks, combined with dietary modifications and increased physical activity under specialist supervision.
Wegovy (semaglutide 2.4 mg) is a once-weekly subcutaneous injection licensed in the UK for weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity. As a glucagon-like peptide-1 (GLP-1) receptor agonist, Wegovy works by mimicking the natural hormone GLP-1, which regulates appetite and food intake by acting on areas of the brain that control hunger.
When you begin treatment, your healthcare provider will prescribe a gradual dose escalation schedule to minimise gastrointestinal side effects. You will typically start with 0.25 mg weekly for four weeks, then increase every four weeks through 0.5 mg, 1 mg, and 1.7 mg, before reaching the maintenance dose of 2.4 mg. This titration period allows your body to adjust to the medication and helps reduce the likelihood of nausea and other digestive symptoms.
During the first few weeks, many patients notice a reduction in appetite and food cravings. You may feel fuller more quickly during meals and experience less interest in snacking between meals. Some people report mild gastrointestinal discomfort initially, which typically improves as treatment continues. It is essential to understand that Wegovy is prescribed as part of a comprehensive weight management programme that includes dietary modifications and increased physical activity—the medication is not a standalone solution but rather a tool to support sustainable lifestyle changes.
Importantly, Wegovy is contraindicated during pregnancy and breastfeeding. In line with NICE Technology Appraisal 875, Wegovy should only be prescribed within specialist tier-3 weight management services that provide comprehensive support.
LOSE WEIGHT WITH MEDICAL SUPPORT — BUILT FOR MEN
Find out if you’re eligible
The most frequently reported side effects of Wegovy are gastrointestinal in nature, particularly during the dose escalation phase. Nausea affects approximately 44% of patients, whilst diarrhoea (30%), vomiting (24%), constipation (24%), and abdominal pain (20%) are also common. These symptoms are generally mild to moderate in severity and tend to diminish over time as your body adapts to the medication.
To manage nausea effectively, consider eating smaller, more frequent meals rather than three large meals daily. Avoid lying down immediately after eating, and choose bland, low-fat foods during periods of discomfort. Some patients report that ginger tea may provide relief, though evidence for this is anecdotal. If you experience vomiting, ensure adequate hydration by sipping water or oral rehydration solutions throughout the day. For constipation, increase your fibre intake gradually, drink plenty of water, and maintain regular physical activity.
Other notable side effects include fatigue, dizziness, and injection site reactions such as redness or itching. Headaches occur in approximately 14% of patients. Gallbladder problems, including gallstones (cholelithiasis), affect approximately 6% of patients. Rare but serious adverse effects include pancreatitis (presenting as severe, persistent abdominal pain radiating to the back) and hypoglycaemia (particularly if you are taking other diabetes medications). People with diabetes should be aware of the risk of diabetic retinopathy complications, especially if blood glucose levels improve rapidly. There have been reports of thyroid C-cell tumours in animal studies, though there is no confirmed link in humans.
If side effects become severe, persistent, or significantly impact your quality of life, contact your GP or prescribing clinician. They may adjust your dose escalation schedule or provide additional management strategies. Never discontinue Wegovy abruptly without medical guidance.
Patients are encouraged to report any suspected side effects via the MHRA Yellow Card Scheme (website: yellowcard.mhra.gov.uk or search 'MHRA Yellow Card' in the Google Play or Apple App Store).
Clinical trial data from the STEP (Semaglutide Treatment Effect in People with obesity) programme provides evidence-based expectations for weight loss with Wegovy. In the pivotal STEP 1 trial, participants lost an average of 14.9% of their initial body weight over 68 weeks, compared to 2.4% with placebo—all alongside lifestyle interventions. However, individual results vary considerably based on adherence, baseline characteristics, and lifestyle factors.
During the initial dose escalation period (months 1–4), weight loss is typically modest, averaging 2–5% of body weight. This gradual start is intentional, allowing your body to adjust whilst minimising side effects. Most significant weight loss occurs between months 4 and 12, once you reach the maintenance dose of 2.4 mg weekly. Many patients continue to lose weight up to 60-68 weeks, after which weight typically plateaus.
It is crucial to set realistic expectations: Wegovy is not a rapid weight loss solution. NICE guidance (TA875) states that treatment should be continued only if patients achieve at least 5% weight loss after 6 months. Approximately 86% of trial participants achieved this threshold. Weight loss may plateau at various points, which is normal and does not necessarily indicate treatment failure. Factors such as metabolic adaptation, changes in physical activity, and dietary adherence all influence outcomes. The maximum licensed treatment duration is 2 years.
Remember that weight is just one measure of success. Many patients experience improvements in cardiovascular risk factors, blood pressure, lipid profiles, and glycaemic control even before significant weight loss occurs. Focus on non-scale victories such as improved mobility, better sleep quality, and enhanced overall wellbeing alongside the number on the scales.
Wegovy is supplied in pre-filled, single-use injection pens designed for subcutaneous administration. Each pen contains one dose and should be injected once weekly, on the same day each week, at any time of day, with or without meals. Consistency in your injection schedule helps maintain stable medication levels and establishes a routine that supports adherence.
Proper injection technique is essential for optimal medication delivery and to minimise injection site reactions. Choose an injection site on your abdomen (at least 5 cm away from your navel), thigh, or upper arm. Rotate injection sites weekly to prevent lipodystrophy (changes in fat tissue under the skin). Before injecting, allow the pen to reach room temperature for approximately 30 minutes, as cold injections may be more uncomfortable. Wash your hands thoroughly and clean the injection site with an alcohol wipe if recommended by your healthcare provider.
To administer the injection, remove the pen cap, place the pen firmly against your skin at a 90-degree angle, and press the dose button until you hear a click. Keep the pen pressed against your skin and count slowly to six to ensure complete dose delivery. You should see the dose counter return to zero. After injection, dispose of the pen safely in a sharps container—never reuse pens or share them with others.
If you miss a dose and it has been less than five days since your scheduled injection, administer it as soon as possible. If more than five days have passed, skip the missed dose and resume your regular schedule with the next dose. Never inject two doses within three days of each other. Store unused pens in the refrigerator (2–8°C) and protect them from light. Once in use, pens may be stored at room temperature (below 30°C) for up to 28 days.
Wegovy is licensed specifically as an adjunct to a reduced-calorie diet and increased physical activity—it is not effective as monotherapy. To maximise your results, you must commit to sustainable lifestyle modifications that complement the medication's appetite-suppressing effects. NICE recommends that Wegovy be prescribed only within specialist weight management services that provide comprehensive behavioural support.
Dietary modifications should focus on creating a moderate calorie deficit whilst ensuring adequate nutrition. Aim for a balanced diet rich in vegetables, fruits, whole grains, and lean proteins. Because Wegovy reduces appetite significantly, some patients struggle to meet their nutritional needs. Adequate protein intake is important to preserve lean muscle mass during weight loss—discuss specific targets with your dietitian as individual needs vary. Consider working with a registered dietitian who can develop a personalised meal plan that accounts for your reduced appetite whilst preventing nutritional deficiencies. Avoid high-fat, greasy foods that may exacerbate gastrointestinal side effects.
Physical activity is crucial for maintaining muscle mass, improving cardiovascular health, and supporting long-term weight maintenance. Current UK guidelines recommend at least 150 minutes of moderate-intensity aerobic activity weekly, plus strength training exercises twice weekly. Start gradually if you are currently sedentary, and increase activity levels progressively. Activities such as brisk walking, swimming, or cycling are excellent options. Resistance training is particularly important to counteract the loss of lean muscle mass that can occur with significant weight loss.
Behavioural strategies include mindful eating practices, stress management techniques, adequate sleep (7–9 hours nightly), and addressing emotional eating patterns. Many specialist weight management services offer cognitive behavioural therapy or group support sessions that can enhance treatment outcomes. Limiting alcohol consumption and smoking cessation are also important lifestyle factors that can improve overall health outcomes. Establish a support network of family, friends, or peer groups who understand your weight management goals.
Regular monitoring is essential to assess treatment efficacy, manage side effects, and identify any complications early. Your healthcare provider will typically schedule follow-up appointments at 4–6 week intervals during dose escalation, then every 3–6 months once you reach the maintenance dose. These appointments will include weight measurements, blood pressure checks, and discussions about side effects and lifestyle adherence.
Key parameters to monitor include body weight, BMI, waist circumference, and improvements in weight-related comorbidities such as type 2 diabetes, hypertension, or dyslipidaemia. Your clinician may order periodic blood tests to assess lipid profiles, HbA1c (if you have diabetes or prediabetes), liver function, and kidney function. NICE guidance recommends discontinuing Wegovy if you do not achieve at least 5% weight loss after 6 months of treatment, as continued treatment is unlikely to provide meaningful benefit.
Between appointments, track your progress using a journal or mobile app. Record your weight weekly (same day, same time, same conditions), food intake, physical activity, and any side effects. This information helps you and your healthcare team make informed decisions about your treatment plan.
If you have diabetes, regular eye examinations are important as rapid improvements in blood glucose control may worsen diabetic retinopathy in some cases. Discuss appropriate ophthalmology follow-up with your healthcare team.
Contact your GP or prescribing clinician urgently if you experience: severe, persistent abdominal pain (possible pancreatitis); signs of gallbladder disease (pain in the upper right abdomen, fever, yellowing of skin or eyes); symptoms of hypoglycaemia if taking other diabetes medications (shakiness, confusion, rapid heartbeat); severe, persistent vomiting or diarrhoea leading to dehydration; changes in vision; or signs of allergic reaction (rash, difficulty breathing, swelling of face or throat). Additionally, seek medical advice if you develop a lump or swelling in your neck, hoarseness, difficulty swallowing, or shortness of breath, as these may indicate thyroid problems. Regular communication with your healthcare team ensures safe, effective treatment and allows for timely adjustments to optimise your weight management journey.
Most patients experience modest weight loss (2–5% of body weight) during the initial 4-month dose escalation period, with the most significant weight loss occurring between months 4 and 12 once the maintenance dose of 2.4 mg weekly is reached.
The most common side effects are gastrointestinal, including nausea (44% of patients), diarrhoea (30%), vomiting (24%), and constipation (24%). These symptoms are typically mild to moderate and diminish over time as your body adjusts to the medication.
Yes, Wegovy must be combined with a reduced-calorie diet and increased physical activity as part of a comprehensive weight management programme. Focus on balanced nutrition with adequate protein, and consider working with a registered dietitian to develop a personalised meal plan.
All medical content on this blog is created based on reputable, evidence-based sources and reviewed regularly for accuracy and relevance. While we strive to keep content up to date with the latest research and clinical guidelines, it is intended for general informational purposes only.
DisclaimerThis content is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional with any medical questions or concerns. Use of the information is at your own risk, and we are not responsible for any consequences resulting from its use.
